Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...

The global psoriasis treatment market is projected to expand at a compound annual growth rate (CAGR) of 8.5% by 2026. Key factors fueling this growth include the rising prevalence of psoriasis, ...

Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to ...

Greater rates of patients with PsO achieved concurrent complete skin and nail clearance with bimekizumab vs adalimumab, ustekinumab, and secukinumab.

On November 6, 2025, Hikma Pharmaceuticals PLC, and its subsidiary Hikma Pharmaceuticals USA Inc., announced the launch of ...

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis ...

Samsung Bioepis has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of ...

(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered ...

Anticipation surrounds Roivant Sciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter. New inv ...

Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including ...

New clinical data confirms Bmab 1200, a biosimilar to ustekinumab, offers equivalent efficacy and safety for treating ...

Horsham: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking to expand approval of ...